Plain-English translation of NCT07579234 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a Phase III clinical trial comparing a new drug called F182112 against standard treatment options for multiple myeloma that has stopped responding to previous medications. The study will enroll about 261 patients and track how long their cancer remains stable—the main measure of how well the medication works. Researchers want to see if this new treatment helps patients live longer without their disease getting worse.
Multiple myeloma patients whose cancer stops responding to standard therapies—especially those who've already tried three main types of medications—have very few good options left. This study exists to find out whether this new treatment can offer these patients better outcomes and longer remission periods.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication F182112 alone, or one of two standard treatment regimens (combinations of approved myeloma drugs). Your doctor will help choose which standard option is best for you before randomization. You'll have regular clinic visits to receive treatment, have blood tests to monitor your response, and be followed until your disease progresses—the study aims to see how long you stay stable on your assigned treatment.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China